JP2023526980A - ハードカプセル剤形及びその使用 - Google Patents

ハードカプセル剤形及びその使用 Download PDF

Info

Publication number
JP2023526980A
JP2023526980A JP2022571817A JP2022571817A JP2023526980A JP 2023526980 A JP2023526980 A JP 2023526980A JP 2022571817 A JP2022571817 A JP 2022571817A JP 2022571817 A JP2022571817 A JP 2022571817A JP 2023526980 A JP2023526980 A JP 2023526980A
Authority
JP
Japan
Prior art keywords
hydroxyvitamin
dosage form
hard capsule
optionally
calcifediol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526980A5 (enExample
Inventor
リーム エラメイン エルシディグ
コルム ナルティ
Original Assignee
エアジェン ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000220 external-priority patent/WO2021205225A1/en
Application filed by エアジェン ファーマ リミテッド filed Critical エアジェン ファーマ リミテッド
Publication of JP2023526980A publication Critical patent/JP2023526980A/ja
Publication of JP2023526980A5 publication Critical patent/JP2023526980A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022571817A 2020-05-31 2021-05-31 ハードカプセル剤形及びその使用 Pending JP2023526980A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection
IBPCT/IB2021/000220 2021-04-06
PCT/IB2021/000376 WO2021245458A1 (en) 2020-05-31 2021-05-31 Hard capsule dosage form and uses thereof

Publications (2)

Publication Number Publication Date
JP2023526980A true JP2023526980A (ja) 2023-06-26
JP2023526980A5 JP2023526980A5 (enExample) 2024-06-06

Family

ID=78831505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571817A Pending JP2023526980A (ja) 2020-05-31 2021-05-31 ハードカプセル剤形及びその使用

Country Status (9)

Country Link
US (2) US20230293552A1 (enExample)
EP (1) EP4157231A1 (enExample)
JP (1) JP2023526980A (enExample)
KR (1) KR20230017192A (enExample)
CN (2) CN115768412A (enExample)
AU (1) AU2021285494A1 (enExample)
CA (1) CA3181945A1 (enExample)
IL (1) IL297885A (enExample)
WO (1) WO2021245458A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245458A1 (en) * 2020-05-31 2021-12-09 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
WO2024063039A1 (ja) * 2022-09-20 2024-03-28 ロンザ株式会社 酸化マグネシウムを含有する遮光性ハードカプセル
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505928A (ja) * 2009-09-24 2013-02-21 キャプシュゲル・ベルジウム・エヌ・ヴィ 耐酸性カプセル
JP2016502562A (ja) * 2012-12-05 2016-01-28 サムスン ファイン ケミカルズ カンパニー リミテッドＳａｍｓｕｎｇｆｉｎｅ Ｃｈｅｍｉｃａｌｓ Ｃｏ．，Ｌｔｄ． 硬質カプセル
JP2018534254A (ja) * 2015-09-25 2018-11-22 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
JP2023520591A (ja) * 2020-04-06 2023-05-17 エアジェン ファーマ リミテッド Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu) * 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
RU2420538C2 (ru) * 2006-10-27 2011-06-10 Пфайзер Продактс Инк. Жесткие капсулы из гидроксипропилметилцеллюлозы и способ их получения
ES2401205T3 (es) * 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
CA2683514C (en) * 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
PT2321273E (pt) * 2008-07-24 2014-12-29 Wisconsin Alumni Res Found Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US12214084B2 (en) * 2017-07-11 2025-02-04 Qualicaps Co., Ltd. Enteric hard capsule
WO2020044314A1 (en) 2018-08-31 2020-03-05 Opko Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using
WO2021245458A1 (en) * 2020-05-31 2021-12-09 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505928A (ja) * 2009-09-24 2013-02-21 キャプシュゲル・ベルジウム・エヌ・ヴィ 耐酸性カプセル
JP2016502562A (ja) * 2012-12-05 2016-01-28 サムスン ファイン ケミカルズ カンパニー リミテッドＳａｍｓｕｎｇｆｉｎｅ Ｃｈｅｍｉｃａｌｓ Ｃｏ．，Ｌｔｄ． 硬質カプセル
JP2018534254A (ja) * 2015-09-25 2018-11-22 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
JP2023520591A (ja) * 2020-04-06 2023-05-17 エアジェン ファーマ リミテッド Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ

Also Published As

Publication number Publication date
CA3181945A1 (en) 2021-12-09
WO2021245458A1 (en) 2021-12-09
EP4157231A1 (en) 2023-04-05
CN120694962A (zh) 2025-09-26
KR20230017192A (ko) 2023-02-03
CN115768412A (zh) 2023-03-07
IL297885A (en) 2023-01-01
AU2021285494A1 (en) 2022-12-08
US20230293552A1 (en) 2023-09-21
US20230330110A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
JP7282832B2 (ja) 安定化調整放出ビタミンｄ製剤及びその投与方法
US20230330110A1 (en) Hard capsule dosage form and uses thereof
AU2021107174A4 (en) Vitamin d pediatric dosage forms, methods of making and using
TWI645864B (zh) 經穩定之修飾釋放維他命ｄ調配物及其服用方法
TWI812891B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
TWI743426B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
HK40033528A (en) Stabilized modified release vitamin d formulation and method of administering same
RU2828673C1 (ru) КАПСУЛЫ ЗАДЕРЖАННОГО ВЫСВОБОЖДЕНИЯ ИЗ МЯГКОГО ЖЕЛАТИНА В СРЕДЕ С БОЛЕЕ ВЫСОКИМ ЗНАЧЕНИЕМ pH
NZ711924B2 (en) Stabilized modified release vitamin d formulation and method of administering same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401